Corrigendum

Following the publication of the Review by Tracy Y Zhu, Lai Shan Tam and Edmund K Li, ‘The socioeconomic burden of systemic lupus erythematosus: state-of-the-art and prospects’, published in the February 2012 issue of Expert Review of Pharmacoeconomics and Outcomes Research (Expert Rev. Pharmacoecon. Outcomes Res. 12[1], 53–69 [2012]; http://www.expert-reviews.com/doi/full/10.1586/erp.11.92), it has been brought to our attention that part of Table 1 on page 55 was incorrectly printed as:

Table 1. Characteristics of study design of cost-of-illness studies.

Design	Definitions	Remarks
Epidemiological approach
Prevalence-based	Estimates the discounted lifelong costs, based on all cases with onset of disease within the period of study, usually 1 year	Useful for drawing decision-makers’ interest for conditions whose burden has been underestimated
Incidence-based	Focuses on the costs of an illness in one period, usually 1 year, and on a cohort of typical patients, irrespective of the onset of the disease	Useful for considering preventative measures and analyzing the management of the illness from the onset until recovery or death

The correct table is shown below:

Table 1. Characteristics of study design of cost-of-illness studies.

Design	Definitions	Remarks
Epidemiological approach
Prevalence-based	Focuses on the costs of an illness in one period, usually 1 year, and on a cohort of typical patients, irrespective of the onset of the disease	Useful for drawing decision-makers’ interest for conditions whose burden has been underestimated
Incidence-based	Estimates the discounted lifelong costs, based on all cases with onset of disease within the period of study, usually 1 year	Useful for considering preventative measures and analyzing the management of the illness from the onset until recovery or death

The authors and editors of Expert Review of Pharmacoeconomics and Outcomes Research would like to sincerely apologize for any inconvenience or confusion this may have caused our readers.